+Follow
CamilleV26
No personal profile
2
Follow
3
Followers
0
Topic
0
Badge
Posts
Hot
CamilleV26
2021-09-03
Great!
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?
CamilleV26
2021-07-01
[Strong]
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575063168744005","uuid":"3575063168744005","gmtCreate":1617533722911,"gmtModify":1617533722911,"name":"CamilleV26","pinyin":"camillev26","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":2,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":815010736,"gmtCreate":1630629485625,"gmtModify":1676530359612,"author":{"id":"3575063168744005","authorId":"3575063168744005","name":"CamilleV26","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575063168744005","authorIdStr":"3575063168744005"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815010736","repostId":"2164684263","repostType":4,"repost":{"id":"2164684263","pubTimestamp":1630629180,"share":"https://ttm.financial/m/news/2164684263?lang=&edition=fundamental","pubTime":"2021-09-03 08:33","market":"us","language":"en","title":"Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?","url":"https://stock-news.laohu8.com/highlight/detail?id=2164684263","media":"Motley Fool","summary":"Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet.","content":"<p>Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet.</p>\n<p>In some ways, it might look and feel like the world is putting the coronavirus in the rearview mirror. But the fact is COVID-19 remains a lingering problem for a slew of corporations that don't have an easy way to work around the challenges linked to the pandemic. Not even all of the blue-chip powerhouses that make up the<b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) are immune to certain headaches. Their stocks have suffered as a result.</p>\n<p>Still, beaten-down stocks can be bargains if they have a good chance of recovering in the foreseeable future.</p>\n<p>With that as the backdrop, here's a rundown of the three biggest DJIA losers from last month. Bargain-hunting investors will find at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the three merits a closer look while at its depressed price.</p>\n<p><b>Worst of the worst</b></p>\n<p>There's no need to dance around the issue. August's biggest losers among the Dow's stocks are<b> <a href=\"https://laohu8.com/S/V\">Visa</a></b> (NYSE:V) and<b>Amgen</b> (NASDAQ:AMGN) -- both with 7% setbacks -- and<b>Boeing</b>(NYSE:BA) with a loss of nearly 5% last month versus the Dow's overall gain of 1.2%.</p>\n<p>For Boeing, the weakness extends a five-month stock price pullback that ultimately stems from a failure to eradicate COVID-19 before the delta variant reaccelerated its spread. The air travel business is not quite back to its full stride, but it's moving in that direction. Boeing is even securing new orders for its once-marred 737 MAX as airlines anticipate a full rebound in the foreseeable future.</p>\n<p>Investors aren't so sure, though, that more virus-related shutdowns are possible and are shedding their Boeing shares just in case travel demand contracts rather than continues to improve. The aircraft maker is simply too vulnerable to even the slightest and most temporary of disruptions.</p>\n<p>Visa's pullback is rooted in similar concerns, although it was made all the more vulnerable by the stock's huge price run-up through late July.</p>\n<p>All told, Visa stock gained 76% between its March 2020 low and this July's high, leaving it primed for profit-taking, which most investors did following the release of fiscal third-quarter results. Quarterly revenue of $6.1 billion was up 27% year over year, easily topping estimates. CFO Vasant Prabhu also made a point of saying during the company's third-quarter conference call that the spread of COVID-19's delta variant wasn't crimping consumer spending. But, as was the case with Boeing, investors aren't quite buying it -- at least not like they were just a month before.</p>\n<p>Even Amgen's setback is linked to the rekindled spread of the coronavirus, although not due to its direct impact on consumer spending. Rather, the company dialed back its full-year earnings guidance, citing logistical difficulties in getting prospective patients in front of doctors. The knee-jerk response to the report was a 6% stock price rout that's worsened in the meantime.</p>\n<p><b>Perception versus perspective</b></p>\n<p>None of the three companies are doomed. Indeed, two years from now, shareholders of all three will likely be struggling to recall the details of their current challenges. If you own or decided to buy any or all of these stocks following their August dips, it wouldn't be the end of the world.</p>\n<p>Still, there's nothing inherently wrong with holding off a bit on a purchase, either.</p>\n<p>Boeing will be fine in the long run. Despite the woes of its 737 MAX program, the company still has more than 5,000 unfilled orders for its various aircraft. Also keep in mind that before the delta variant of COVID-19, some airlines were moving back to pre-pandemic levels, promising a return to profitability sometime this year. But the stock itself remains overly sensitive to even hints of prospective problems. There's no clarity as to when the market will start seeing Boeing's glass as half full rather than half empty. Until then, the risk outweighs the reward.</p>\n<p>Visa's in a similar (although not identical) boat, subject to perceptions as much as to its fiscal reality. Despite last month's pullback, the stock remains overbought, tempting more shareholders to lock in gains while its price remains firm.</p>\n<p>The only name among the three that's a truly compelling buy here and now is Amgen.</p>\n<p>Yes, the pandemic remains a stumbling block, but last month's selling has pulled the stock back to its late-2019 prices; the market is pricing in bigger problems than it actually has. This is the same company behind blockbuster drugs like Otezla, Enbrel, and cholesterol-fighting Repatha, just to name a few. It then has about 17 other drugs in its portfolio to round its list of revenue creators and dozens more in its pipeline.</p>\n<p>There's certainly no lack of opportunity here, and newcomers will be stepping into Amgen's deep R&D bench while its dividend yield (based on a payout that isn't exactly threatened at this time) is a healthy 3.2%.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 08:33 GMT+8 <a href=https://www.fool.com/investing/2021/09/02/time-to-buy-dow-jones-worst-performing-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet.\nIn some ways, it might look and feel like the world is putting the coronavirus in the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/02/time-to-buy-dow-jones-worst-performing-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXD":"道指两倍做空ETF","UDOW":"道指三倍做多ETF-ProShares","BA":"波音","SDOW":"道指三倍做空ETF-ProShares","DJX":"1/100道琼斯","DOG":"道指反向ETF","DDM":"道指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/09/02/time-to-buy-dow-jones-worst-performing-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164684263","content_text":"Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet.\nIn some ways, it might look and feel like the world is putting the coronavirus in the rearview mirror. But the fact is COVID-19 remains a lingering problem for a slew of corporations that don't have an easy way to work around the challenges linked to the pandemic. Not even all of the blue-chip powerhouses that make up theDow Jones Industrial Average (DJINDICES:^DJI) are immune to certain headaches. Their stocks have suffered as a result.\nStill, beaten-down stocks can be bargains if they have a good chance of recovering in the foreseeable future.\nWith that as the backdrop, here's a rundown of the three biggest DJIA losers from last month. Bargain-hunting investors will find at least one of the three merits a closer look while at its depressed price.\nWorst of the worst\nThere's no need to dance around the issue. August's biggest losers among the Dow's stocks are Visa (NYSE:V) andAmgen (NASDAQ:AMGN) -- both with 7% setbacks -- andBoeing(NYSE:BA) with a loss of nearly 5% last month versus the Dow's overall gain of 1.2%.\nFor Boeing, the weakness extends a five-month stock price pullback that ultimately stems from a failure to eradicate COVID-19 before the delta variant reaccelerated its spread. The air travel business is not quite back to its full stride, but it's moving in that direction. Boeing is even securing new orders for its once-marred 737 MAX as airlines anticipate a full rebound in the foreseeable future.\nInvestors aren't so sure, though, that more virus-related shutdowns are possible and are shedding their Boeing shares just in case travel demand contracts rather than continues to improve. The aircraft maker is simply too vulnerable to even the slightest and most temporary of disruptions.\nVisa's pullback is rooted in similar concerns, although it was made all the more vulnerable by the stock's huge price run-up through late July.\nAll told, Visa stock gained 76% between its March 2020 low and this July's high, leaving it primed for profit-taking, which most investors did following the release of fiscal third-quarter results. Quarterly revenue of $6.1 billion was up 27% year over year, easily topping estimates. CFO Vasant Prabhu also made a point of saying during the company's third-quarter conference call that the spread of COVID-19's delta variant wasn't crimping consumer spending. But, as was the case with Boeing, investors aren't quite buying it -- at least not like they were just a month before.\nEven Amgen's setback is linked to the rekindled spread of the coronavirus, although not due to its direct impact on consumer spending. Rather, the company dialed back its full-year earnings guidance, citing logistical difficulties in getting prospective patients in front of doctors. The knee-jerk response to the report was a 6% stock price rout that's worsened in the meantime.\nPerception versus perspective\nNone of the three companies are doomed. Indeed, two years from now, shareholders of all three will likely be struggling to recall the details of their current challenges. If you own or decided to buy any or all of these stocks following their August dips, it wouldn't be the end of the world.\nStill, there's nothing inherently wrong with holding off a bit on a purchase, either.\nBoeing will be fine in the long run. Despite the woes of its 737 MAX program, the company still has more than 5,000 unfilled orders for its various aircraft. Also keep in mind that before the delta variant of COVID-19, some airlines were moving back to pre-pandemic levels, promising a return to profitability sometime this year. But the stock itself remains overly sensitive to even hints of prospective problems. There's no clarity as to when the market will start seeing Boeing's glass as half full rather than half empty. Until then, the risk outweighs the reward.\nVisa's in a similar (although not identical) boat, subject to perceptions as much as to its fiscal reality. Despite last month's pullback, the stock remains overbought, tempting more shareholders to lock in gains while its price remains firm.\nThe only name among the three that's a truly compelling buy here and now is Amgen.\nYes, the pandemic remains a stumbling block, but last month's selling has pulled the stock back to its late-2019 prices; the market is pricing in bigger problems than it actually has. This is the same company behind blockbuster drugs like Otezla, Enbrel, and cholesterol-fighting Repatha, just to name a few. It then has about 17 other drugs in its portfolio to round its list of revenue creators and dozens more in its pipeline.\nThere's certainly no lack of opportunity here, and newcomers will be stepping into Amgen's deep R&D bench while its dividend yield (based on a payout that isn't exactly threatened at this time) is a healthy 3.2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151861331,"gmtCreate":1625071980023,"gmtModify":1703735595534,"author":{"id":"3575063168744005","authorId":"3575063168744005","name":"CamilleV26","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575063168744005","authorIdStr":"3575063168744005"},"themes":[],"htmlText":"[Strong] ","listText":"[Strong] ","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151861331","repostId":"1137680554","repostType":4,"isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":815010736,"gmtCreate":1630629485625,"gmtModify":1676530359612,"author":{"id":"3575063168744005","authorId":"3575063168744005","name":"CamilleV26","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575063168744005","idStr":"3575063168744005"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815010736","repostId":"2164684263","repostType":4,"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151861331,"gmtCreate":1625071980023,"gmtModify":1703735595534,"author":{"id":"3575063168744005","authorId":"3575063168744005","name":"CamilleV26","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575063168744005","idStr":"3575063168744005"},"themes":[],"htmlText":"[Strong] ","listText":"[Strong] ","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151861331","repostId":"1137680554","repostType":4,"repost":{"id":"1137680554","pubTimestamp":1625061646,"share":"https://ttm.financial/m/news/1137680554?lang=&edition=fundamental","pubTime":"2021-06-30 22:00","market":"us","language":"en","title":"May home sales rebound to highest level since 2005, shocking even the Realtors","url":"https://stock-news.laohu8.com/highlight/detail?id=1137680554","media":"CNBC","summary":"KEY POINTS\n\nPending home sales surprised the experts, rising 8% in May\nRealtors point to lower mortg","content":"<div>\n<p>KEY POINTS\n\nPending home sales surprised the experts, rising 8% in May\nRealtors point to lower mortgage rates for some of the sales gains.\nPending sales were strongest in the Northeast and West.\n\nThe ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/30/may-home-sales-rebound-to-highest-level-since-2005.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>May home sales rebound to highest level since 2005, shocking even the Realtors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMay home sales rebound to highest level since 2005, shocking even the Realtors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:00 GMT+8 <a href=https://www.cnbc.com/2021/06/30/may-home-sales-rebound-to-highest-level-since-2005.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nPending home sales surprised the experts, rising 8% in May\nRealtors point to lower mortgage rates for some of the sales gains.\nPending sales were strongest in the Northeast and West.\n\nThe ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/30/may-home-sales-rebound-to-highest-level-since-2005.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.cnbc.com/2021/06/30/may-home-sales-rebound-to-highest-level-since-2005.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1137680554","content_text":"KEY POINTS\n\nPending home sales surprised the experts, rising 8% in May\nRealtors point to lower mortgage rates for some of the sales gains.\nPending sales were strongest in the Northeast and West.\n\nThe pandemic-induced housing boom may not be over quite yet. Despite recent months of softening sales, buyers came back remarkably strongly in May.\nPending home sales, a measure of signed contracts on existing homes, jumped an unexpectedly high 8% in May compared with April, according to the National Association of Realtors. Analysts expected a 1% drop. This is the highest level of sales activity for May since 2005.\nSales were up 13% from May of 2020, when the housing market was just beginning to come back from the coronavirus lockdown. Pending contracts are a forward-looking indicator of closed home sales.\n“May’s strong increase in transactions – following April’s decline, as well as a sudden erosion in home affordability – was indeed a surprise,” said Lawrence Yun, NAR’s chief economist. “The housing market is attracting buyers due to the decline in mortgage rates, which fell below 3%, and from an uptick in listings.”\nAfter falling quite sharply in April, the average on the 30-year fixed hovered in a tight range throughout May, giving some buyers at least a little relief on potential monthly payments.\nBut sky-high home prices have been a major concern. In April, the much watched S&P Case-Shiller National Home Price Index was up over 14% year over year, the largest gain in its 30-year history.\nThe Realtors report even higher gains in the median home price, some of which is skewed due to the fact that more of the sales activity is happening on the higher end of the market, where listings are more plentiful. The low end of the market is barely budging, as first-time buyers struggle for meager listings. Investors, the majority of whom use cash, are also more prevalent at the lower end of the market.\n“While these hurdles have contributed to pricing out some would-be buyers, the record-high aggregate wealth in the country from the elevated stock market and rising home prices are evidently providing funds for home purchases,” Yun said.\nRegionally, pending home sales jumped 15.5% in the Northeast month-to-month. In the Midwest, sales rose 6.7%. Sales in the South rose 4.9% from April. In the West, they rose 10.9%.\nTight supply of existing homes has been a major factor, but that supply did rise slightly in May compared with April, although it was still historically low. Supply of existing homes is about 20% below year-ago levels. Homebuilders have also not been ramping up production as quickly as the market is demanding.\nSales of newly built homes in May, which are also measured by signed contracts, fell nearly 6% from April, as builders continued to raise prices. The median price of a newly built home sold in May was up 18%, according to the U.S. Census. Builders have seen soaring costs for land, labor and materials. While the price of lumber has come down dramatically in the last month, it is still well above pre-pandemic levels.","news_type":1},"isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
